Broker tips: Aviva, Amaroq, Croda

16th Nov 2026 14:39

(Sharecast News) - Analysts at Berenberg raised their target price on Aviva to 850p from 820p on Monday after the insurer's third-quarter update highlighted stronger-than-expected growth in UK personal lines and a significantly improved outlook for its bulk annuity business.

Berenberg said investor concerns heading into the update had centred on whether growth in UK personal lines would slow following the integration of Direct Line. Instead, premiums increased 5.6% year-on-year to £1.6bn, helped by new partnership wins and positive underlying trading, prompting a favourable market reaction.

Berenberg also pointed to a sharp improvement in Aviva's bulk purchase annuity outlook. Having written £1.9bn of annuity business in the first nine months of the year, the insurer was now targeting a further £3.8bn of transactions in the fourth quarter, implying close to £6bn of total deals for 2026 - comfortably ahead of both the broker's and market expectations.

Elsewhere, Aviva's wealth business maintained strong momentum, with net inflows increasing 29% year-on-year in the third quarter. Not all divisions performed as strongly, however. Berenberg highlighted softer trading in UK commercial insurance and Canada, where premium growth was largely flat and profitability was impacted by a series of large catastrophe losses.

Despite those weaknesses, the German bank believes Aviva remains well positioned given the strength of its personal lines, wealth and retirement operations, and maintained its 'buy' recommendation on the stock, while lifting earnings forecasts and its valuation.

Canaccord Genuity upgraded Amaroq to 'buy' from 'speculative buy' on Monday and raised its target price to 160p from 140p, citing stronger-than-expected production, a growing cash position and improving confidence in the group's 2027 outlook.

The Canadian bank said Amaroq had delivered a second consecutive quarterly beat, with third-quarter gold production reaching 12,600 ounces, comfortably ahead of its forecast of 11,600 ounces and higher than any quarterly production estimate it currently has before 2028. As a result, Canaccord said it had a high degree of confidence in the company's near-term production profile.

Canaccord also highlighted Amaroq's strengthening balance sheet, with cash increasing to CAD $51.5m (£27.34m), ahead of expectations, while working capital rose to around CAD $70m (£37.16m). Canaccord said the company was well funded to support ongoing operations, exploration activities and development initiatives.

Third-quarter revenue came in at CAD $65m (£34.51m), above forecasts, while gross profit of CAD $45m (£23.89m) also exceeded expectations as higher realised gold prices and strong grades helped offset slightly lower sales volumes.

Management maintained its full-year production and cost guidance, but Canaccord believes there to be scope for further upside in both fourth-quarter and 2027 production. The broker noted that grades have consistently outperformed its estimates throughout 2026 and expects a continued focus on higher-grade production to support cash generation.

Reflecting stronger operational performance and an improved outlook, Canaccord lifted its valuation and said upcoming drilling results from Nalunaq, Nanoq and other Greenland projects could provide additional catalysts.

Deutsche Bank upgraded Croda to 'buy' from 'hold' on Monday and lifted its price target on the stock to 4,100p from 3,300p as it said the group's recovery was gaining visibility.

The bank said the operational recovery was already underway, strengthening growth and improving execution, supported by self-help, provide greater earnings visibility. In addition, consumer care was accelerating, and the 2028 framework provides a credible path to higher margins and free cash flow.

"We see a double-digit earnings per share growth profile, including a likely buyback, at a compelling valuation," said Deutsche. "This is despite conservative Life Sciences assumptions that leave the business below its earnings potential through 2028."

DB noted that the shares have started to recover, but said it sees further upside, with eventual life sciences normalisation and breakthrough growth in pharma providing additional optionality.